AB8939

DRUG2 trials

Sponsors

Ab Science, AB Science

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in RelapseMyelodysplastic Syndrome Acute Myeloid Leukemia

Phase 1

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

RecruitingNCT05211570

AB ScienceAcute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia

Start: 2022-06-01End: 2026-12-31Target: 78Updated: 2025-10-02

A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia

Not yet recruitingCTIS2024-516641-39-00

Ab ScienceAcute Myeloid Leukemia

Target: 60Updated: 2025-06-16